BioVie Inc. (OTCQB: BIVI; up-listing to NASDAQ) Approximately $15,000,000 of units, with each unit consisting of one share of Class A common stock and one-half (1/2) of one warrant, each whole warrant exercisable for one share of common stock. After giving effect to the planned 1:125 reverse stock split. The final public offering price will be determined through negotiation between us and the lead underwriters in the offering and the recent market price used throughout this prospectus may not be indicative of the final offering price

BlackRock Health Sciences Trust II is a newly-organized, non-diversified, closed-end management investment company with no operating history. The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation.

Annovis is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD).

We are a biotechnology company focusing on early cancer screening and detection. We market and sell a multi-cancer screening and detection test that uses our innovative, patented cancer differentiation analysis, or CDA, technology and our proprietary cancer-detection device, or CDA device.

We are a provider of commercial flooring solutions, including sales, installation and maintenance services for existing and new commercial buildings.

We are a provider of healthcare information, education, and training services to healthcare professionals and the public in China.

Multimedia service provider based in Shenyang, China, with business relationships with national advertising clients.

We are a digital cinema company who designs, manufactures, integrates, installs and distributes a full suite of proprietary and custom designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements.

We are a returns-focused company formed to pursue oil and natural gas mineral and royalty interest opportunities in leading oil-weighted onshore domestic resource plays.

Our goal is to become a diversified high-tech Internet company targeting fast growing technology sectors primarily in China. Our business segments primarily consist of online games and electric vehicles through our joint venture agreement with Faraday&Future Inc. or F&F.

We are a rapidly-growing online peer-to-peer lending marketplace facilitating loans between borrowers and investors, providing borrowers accessible, affordable credit and offering investors attractive risk-adjusted returns. From our inception through June 30, 2018, we have matched loan transactions with an aggregate value of approximately RMB4.99 billion ($743.53 million). We primarily conduct our businesses in Guangdong Province, China and service exclusively Chinese borrowers and investors.

We are a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.

We are a rapidly-growing manufacturer and distributor of environmentally-friendly, single-use disposable products primarily used in restaurants and foodservice settings. We supply a wide range of products for the foodservice industry, including food packaging, containers, tableware, cups, lids, cutlery and straws.

We are a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain.

Independent insurance distribution firm.

Progyny is a leading benefits management company specializing in fertility and family building benefits solutions in the United States.

We are a development stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors.

We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.

We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases.

Youdao has developed and used technologies to provide learning content, applications and solutions to users of all ages

We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

We are an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on our patented Thin Film Freezing, or TFF, technology platform.

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

We have built and operate an open end-to-end cloud robot system, and offer it as a service to the world.

We are a growth-oriented, independent oil and natural gas company focused on rapidly growing our reserves, production and cash flow through the acquisition, exploration, development and production of oil, natural gas, and natural gas liquids, or NGLs, reserves in the Permian Basin.

UPLISTING: We are FinTech company and payment facilitator (“PayFac”) that focuses on a suite of products in the merchant services and payment facilitator verticals and provides integrated business solutions to merchants throughout the United States.

Aesthetic medical service company.

We are a leading independent online insurance product and service platform in China that is not affiliated with insurance companies or other insurance industry participants.

We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

FOLLOW-ON OFFERING: Nasdaq uplisting; VerifyMe, Inc. (“VerifyMe,” the “Company,” “we” or “us”) is a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products.

We are a pioneer and leader in China’s used car financing market, focusing on facilitating loans from financial institutions to prime borrowers in used car transactions.

We are a market-leading consumer products company with a presence in 95% of households across the United States.

We are a leading and fast-growing precision oncology company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.

We operate the largest co-working space community in China in terms of the number of co-working spaces, aggregate managed area and number of cities covered in China as of September 30, 2019, according to Frost & Sullivan.

We are a high-growth, healthcare and wellness company that sells topical products to improve immune health, neuromuscular health and skin barrier health.

We are a newly formed commercial real estate finance company. Our strategy is to originate, structure and invest in first mortgage loans, mezzanine loans, preferred equity and alternative structured financings in commercial real estate properties, as well as multifamily commercial mortgage backed securities, or CMBS, securitizations, or collectively our target assets.

We are a membership-based primary care platform with seamless digital health and inviting in-office care, convenient to where people work, shop, live and click.

We are a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies.

We are a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs.